Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.